Turning Negatives into Positives: Re-expressing Receptors in Receptor Negative Breast Cancer

Clinical Trial

Summary: It is estimated that 20% of women diagnosed with breast cancer in the state of California will have hormone receptor-negative (HRN) invasive breast cancer, an aggressive subtype of breast cancer that also disproportionately affects young women, African American women, and Hispanic women. HRN breast cancers are characterized by the failure of these tumors to make proteins (called receptors) that allow the tumors to respond to anticancer medications that are normally given to treat cancers that make the estrogen receptor and progesterone receptor proteins. Recent experiments in the laboratory indicate that a class of drugs called histone deacetylase (HDAC) inhibitors are able to cause HRN breast cancer cells to make the estrogen and/or progesterone receptor proteins. It is widely accepted that by treating hormone receptor-producing breast cancer with anti-hormone drugs, the risk of cancer recurrence and death are significantly reduced. Laboratory experiments also show that HRN breast cancer cells will respond for the first time to drugs that are normally effective against breast cancer cells that produce hormone receptors, which means that the cancer cells become effectively hormone receptor-positive. One of the ways that HDAC inhibitors may achieve this effect is by "turning on" genes that are "turned off" by enzymes called HDACs. Blockage of HDACs by HDAC inhibitors appears to be the mechanism by which HDAC inhibitors are able to turn on estrogen and progesterone receptor production in HRN breast cancer cells and make these newly hormone receptor-producing breast cancer cells responsive to anti-cancer medications that target the estrogen and/or progesterone receptor.

The question(s) or central hypotheses of the research: The observation that HDAC inhibitors are capable of making HRN breast cancer cells behave like hormone receptor-positive breast cancer cells raises the possibility that women with HRN breast cancer may someday be effectively treated with anti-cancer medications that are normally ineffective against HRN breast cancer. However, while these laboratory experiments are promising, a key question is whether or not HDAC inhibitors are able to turn HRN breast cancers into hormone receptor-positive breast cancers in humans. In this proposed investigation, we seek to answer this question by determining if, and to what degree, HDAC inhibitors are capable of stimulating production of the estrogen and progesterone receptor proteins in women with HRN invasive breast cancer.

Eligibility: Women with newly diagnosed triple negative breast cancer measuring 2cm or more who have not yet undergone surgery.

Location: University of Southern California (USC).

Contact: For more information about this clinical trial, please contact Jacqueline Major, R.N. at 323-226-6354.

Funding: Funded by the California Breast Cancer Research Program.

Find Us On:

Follow us on Facebook

Follow us on Twitter

Our Blog:

Fighting To Win Is All We Can Do & We Need To Do It Together !!

August 4, 2013

I have always been a hard-working person, trying to never let anyone down. I love being a mom to my teenage daughter and my three dogs. I have an amazing, supportive husband and we just celebrated our Anniversary of 20 years. I do everything in life to be that good person! I am dedicated to work and my family, paying my bills, going for regular check-ups, and being there for everyone else in their time of need. Basically, I'm just always doing what is RIGHT and GOOD! I now struggle with recently being diagnosed and going through the fight with breast cancer. Who knew that I would eventually find myself with triple negative breast cancer...what did I do wrong? Why me?

Read More »

Bikram Yoga Saved My Life

September 27, 2013

My breast cancer story has a little bit of a different twist than most. I was one who did not discover a lump on my breast. My discovery was via a lump under my armpit which made practicing Bikram Yoga very painful.

Read More »

The BROCADE Study: A Clinical Research Study for People Living with BRCA1/2+ Advanced Breast Cancer

Men and women living with advanced breast cancer due to a BRCA1/2 gene mutation may qualify for a new clinical research study known as the BROCADE Study. This study will determine the safety and effectiveness of veliparib, an experimental anti-cancer drug, in combination with chemotherapy. You may qualify for the study if you are 18 years of age or older, have metastatic or locally recurrent breast cancer and a BRCA1 or 2 mutation, and have not received more than two prior cancer treatments for advanced breast cancer.

People who enroll in the study will be randomized (like flipping a coin) in a 1:1:1 ratio to one of three study treatment groups: veliparib with temozolomide, veliparib with carboplatin and paclitaxel, or placebo with carboplatin and paclitaxel. Temozolomide, carboplatin, and paclitaxel are chemotherapy drugs approved for use in routine cancer care. A placebo is a look-alike pill with no active ingredients. Participants may receive compensation or reimbursement for travel to and from the study center.

If you are interested in learning more about this study, talk to your oncologist, visit the BROCADE Study website at www.BROCADEStudy.com , or call + 1 855 5ONCOLOGY (+ 1 855 566 2656) to speak with an experienced study nurse to determine if the BROCADE Study is right for you.